Survival
Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis
Cancers 2026 August 11 [Link] Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz Abstract Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO…
Read MoreSex-Specific Patterns of Asbestos Exposure and Prognostic Biomarkers in Surgically Treated Pleural Mesothelioma: A Retrospective Cohort Study
Cancers 2026 August 14 [Link] Nicolas Pinzon, Shubham Gulati, Andrew Del Re, Emanuela Taioli, Raja Flores, Andrea S Wolf, Stephanie Tuminello Abstract Background/objectives: Sex-based differences in asbestos exposure and tumor biology in pleural mesothelioma (PM) remain incompletely characterized. As an expert tertiary center, we sought to systematically characterize asbestos exposure by sex and assess biomarker…
Read MorePrognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis
Annals of Surgical Oncology 2026 August 25 [Link] Jan Philipp Ramspott, Anna Kolmhofer, Ibrahim Büdeyri, Michael Weitzendorfer, Stephan Regenbogen, Lukas Schabl-Cayron, Philipp Schredl, Alexander D Bungert, Klaus Emmanuel, Dino Bekric, Jaroslav Presl, Andreas Pascher, Daniel Neureiter, Tarkan Jäger Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive disease in which cytoreductive surgery…
Read MoreIdentification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy
Discover Oncology 2026 July 25 [Link] Jing Ding, Xuefeng Huang, Wenxiu Yao, Tongyu Lin Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with increasing incidence, high mortality, and limited treatment options. Disulfidptosis, a newly identified form of regulated cell death, may play an important role in cancer, but its relevance in PM…
Read MoreADRB2 modulates asbestos-induced pleural mesothelioma progression by influencing IL-17/NF-κB-related inflammatory signalling: An integrated network toxicology, multi-omics and experimental study
Chemico-Biological Interactions 2026 October 1 [Link] Shaoyang Huang, Dandan Gu, Jintao He, Guangsheng Hou, Jundong Wang, Zhengliang Li, Min Yu, Jiangyan Li, Wei Xiong Abstract Pleural mesothelioma (PM) is a highly aggressive asbestos-related malignancy with a poor prognosis and limited early diagnostic options. In this study, network toxicology and integrated multi-omics analyses were used to…
Read MoreRetrospective cohort study on prognostic factors of malignant pleural effusion secondary to pleural mesothelioma
Journal of Thoracic Disease 2026 July 31 [Link] Xin Qiao, Jing-Jing Zhang, Bin Liu, Jian-Wen Qin Abstract Background: Malignant pleural effusion (MPE) frequently complicates pleural mesothelioma; however, prognostic determinants for this condition, particularly pleural fluid biomarkers, have yet to be comprehensively characterized. This study sought to assess the prognostic utility of clinical profiles and laboratory…
Read MorePrognostic Significance of B7-H3 Expression and CD163+ Tumor-Associated Macrophage Infiltration in Mesothelioma
International Journal of Molecular Sciences 2026 August 3 [Link] Tülay Koç, Ramazan Oğuz Yüceer, Tuncay Altay, Neslihan Taş, Serkan Çelikgün Abstract Mesothelioma is a rare, aggressive malignancy with poor prognosis. B7-H3 (CD276), an immune checkpoint molecule, and CD163-positive tumor-associated macrophages (TAMs) contribute to tumor progression and immune evasion. This study evaluated the prognostic impact of…
Read MoreInsights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines
Thoracic Cancer 2026 August [Link] Yani Wu, Fang Cao, Jiayin Dai, Zhenli Yang, Yanli Zhu, Dongmei Lin, Xiaocui Bian, Yuqin Liu Abstract Background: Pleural mesothelioma (PM) is an aggressive cancer with limited therapeutic options and poor prognosis, necessitating comprehensive model systems for mechanistic studies and drug discovery. Methods: Tumor cells were isolated from malignant pleural…
Read MoreLow baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma
Lung Cancer 2026 September [Link] Antoine Torchiat, Karina Silina, Arya Ashok Nair, Laura Viktoria Heeb, Isabelle Opitz, Anurag Gupta, Alessandra Curioni-Fontecedro Abstract Introduction: The cyclic GMP-AMP synthase (cGAS)/STING pathway, a central DNA-sensing mechanism, is known to activate anti-tumor immune response but may also promote tumor progression when chronically activated. Given the role of asbestos-induced chronic…
Read MoreEfficacy of Perioperative Platinum-Pemetrexed Chemotherapy Combined With Pleurectomy/Decortication for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July 25 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Kyoshiro Takegahara, Takashi Kijima, Seiki Hasegawa, Soichiro Funaki Abstract Background: The optimal timing of chemotherapy in multimodal treatment of pleural mesothelioma remains unclear. This study evaluated the efficacy of adjuvant chemotherapy (AC) after neoadjuvant chemotherapy (NAC)…
Read More
Skip to content